A news brief in the Nov. 3, 2004, issue of BioWorld Today should have said that Amylin Pharmaceuticals Inc., along with Eli Lilly and Co. and Alkermes Inc., initiated a Phase II multidose study of exenatide long-acting release in patients with Type II diabetes using a once-a-week dosing regimen.

Editor's Note: The correction has been made in BioWorld Online.